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Implementing Evidence-Based Alcohol
Interventions in a Resource-Limited Setting:
Novel Delivery Strategies in Tomsk, Russia
Sonya S. Shin, MD, MPH, Viktoriya Livchits, MD, MS, Adrianne K. Nelson, MPH, MSc,
Charmaine S. Lastimoso, MPH, RN, Galina V. Yanova, MD, PhD, Sergey A. Yanov, MD,
Sergey P. Mishustin, MD, Hilary S. Connery, MD, PhD, and Shelly F. Greenﬁeld, MD, MPH
Effectiveimplementationofevidence-basedinterventionsin“real-world”settingscanbechallenging.
Interventions based on externally valid trial ﬁndings can be even more difﬁcult to apply in resource-
limited settings, given marked differences—in provider experience, patient population, and health
systems—between those settings and the typical clinical trial environment. Under the auspices of the
Integrated Management of Physician-Delivered Alcohol Care for Tuberculosis Patients (IMPACT)
study, a randomized, controlled effectiveness trial, and as an integrated component of tuberculosis
treatment in Tomsk, Russia, we adapted two proven alcohol interventions to the delivery of care to
200 patients with alcohol use disorders. Tuberculosis providers performed screening for alcohol use
disordersandalsodeliverednaltrexone(withmedicalmanagement)orabriefcounselingintervention
either independently or in combination as a seamless part of routine care. We report the innovations
and challenges to intervention design, training, and delivery of both pharmacologic and behavioral
alcohol interventions within programmatic tuberculosis treatment services. We also discuss the
implications of these lessons learned within the context of meeting the challenge of providing
evidence-based care in resource-limited settings. (HARV REV PSYCHIATRY 2012;20:58–67.)
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INTRODUCTION
Alcoholusedisorders(AUDs)areundertreatedintheUnited
States and worldwide, despite their high medical costs,
social consequences, and role in the incidence and sever-
ity of other diseases—in particular, diseases of poverty. In
the United States, AUDs rank seventh among the leading
causes of premature death and disability, as measured in
disability-adjusted life years.1 In addition to contributing
heavily to chronic morbidity, AUDs contribute causally to
13 of the top 20 causes of mortality.1,2 Yet, such ﬁgures in
the United States pale in comparison to global estimates of
the burden of AUDs. The countries with the highest alco-
hol consumption levels in the world are clustered in eastern
Europe, particularly in Russia and the other countries of
the former Soviet Union, though lower-income countries in
southern Africa and South America also have exceptionally
high rates of consumption.2 Alcohol dependence is an estab-
lished cause of 12 of the 20 leading global causes of death.2,3
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It is therefore not surprising that alcohol-attributable
deaths have risen in the past decade.2 Worldwide, the World
Health Organization (WHO) estimates alcohol use caused
3.2%ofdeathsand4.0%oftotaldisability-adjustedlifeyears
in 2009.4 Despite growing recognition of the global impact of
AUDs, particularly in lower- and middle-income countries,4
the health services available for diagnosing and treating
AUDs in such settings are appallingly scarce.5,6 In addi-
tion, despite the clear evidence that screening and counsel-
ing for AUDs is highly cost-effective and likely cost saving,7
evidence-based screening tools and interventions are often
difﬁcult to implement in resource-limited settings because
of marked differences in provider experience, patient popu-
lations, and health systems.
Russia provides an instructive example of the disparity
between the overwhelming need for alcohol care and the
limited options available to most individuals, particularly
those marginalized by poverty and stigma. Alcohol con-
sumption has contributed to the marked rise in mortality in
Russia over the past two decades. Between 1992 and 2001,
an excess of 2.5–3 million deaths among Russian adults in
middle age occurred over a projection based on 1991 mor-
tality estimates.8 Most experts consider alcohol to be the
most important factor driving these trends, implicated di-
rectly or indirectly in approximately one-third of all Russian
deaths.9−13 Although little data are available for alcohol use
in Tomsk, the available information suggests that it falls to-
ward neither the high nor low extreme for Russian oblasts.14
One study led by the Russian Cancer Center gathered mor-
tality data from 50,066 households in Tomsk, Bernaul, and
Biysk with a deceased member from 1990 to 2001. They
found that 52% of total mortality for adults 15–54 years
could be attributed to alcohol use and that the changes in
the number of alcohol-related deaths may account for the
large ﬂuctuation of mortality in Russia as a whole during
that period.15 Another study using anatomical pathology to
examine causes of violent death in the Tomsk area observed
the presence of ethyl spirit in 63.2% of bodies examined.16
The convergence of AUDs with other diseases of poverty
has implications for Russia’s ability to control the rising
tides of tuberculosis (TB) and human immunodeﬁciency
virus (HIV) disease.17,18 TB patients with AUDs are
at increased risk of poor treatment outcomes such as
default, failure, and death.19 In a recent study, it was
determined that 55% of TB patients in St. Petersburg and
70% in Ivanovo had AUDs.20 Also intimately linked to
alcohol use is the HIV epidemic in Russia, which affects
a larger percentage of its inhabitants than any other
European country. In Russia, alcohol use is consistently
and strongly associated with HIV risk behavior across a
spectrum of high- and low-risk populations.21−28 Abdala and
colleagues23 found that in St. Petersburg both intravenous
drug users and those not using IV drugs were more likely to
have multiple sexual partners if they reported having sex
while drinking alcohol. Alcohol use has also been linked to
increased drug-related risk in St. Petersburg, including use
of unclean needles.24 The impact of alcohol use on TB and
HIV risk in Russia reﬂects associations that have been well
documented at the global level.2,29−33
Underdiagnosis, undertreatment, and lack of evidence-
based interventions (EBIs) are the norm for alcohol
management in most of Russia.20,34 Because AUDs are
generally managed by addiction specialists (narcologists),
general practitioners rarely either screen for AUDs or of-
fer brief counseling interventions (BCIs).13 Patients have
numerous disincentives for seeking alcohol care, including
out-of-pocket payment for services and their ofﬁcial registry
within Narcology Services, which can result in difﬁculty
seeking employment, employment loss, and restrictions in
owning or driving a car. Medical culture in Russia is heavily
reliant on pharmacologic therapies, but the Russian health
care system provides limited access to evidence-based phar-
macotherapies for AUDs—which are often prohibitively ex-
pensive anyway.
In many resource-limited settings, structural factors (in
addition to individual-level characteristics) strongly shape
health-seeking behavior and one’s ability to adhere to
treatment.35 In order to overcome such barriers to alcohol
care, innovative health delivery strategies must integrate
routine diagnosis and treatment into services that are free
of charge and readily accessed by marginalized patients who
would not otherwise seek alcohol treatment. One example
of strong infrastructure for such settings is WHO’s sug-
gested strategy for managing TB: Directly Observed Treat-
ment, Short-Course, or DOTS.36 This therapy is considered
the international standard for TB management in many
lower- and middle- income countries, and includes directly
observed treatment with TB medications and programmatic
components (e.g., outreach to ﬁnd individuals who default
from care, and incentives and enablers such as transporta-
tion and meal vouchers to help patients attend their daily
visits) to keep individuals in TB care for the six months re-
quired to complete treatment (i.e., case holding). In essence,
DOTS is designed with programmatic elements to overcome
manyofbarrierstohealthservicesexperiencedbymarginal-
ized patients in resource-limited settings.
To take advantage of the existing DOTS infrastructure,
we developed an integrated model of alcohol and TB care
that would deliver screening and treatment services for in-
dividuals with AUDs as part of routine TB services. We then
implemented these strategies (under both programmatic
and research auspices) within the Tomsk Oblast Tuber-
culosis Services, in an effort to decrease alcohol-related
morbidity and improve TB treatment outcomes. This article
provides a case study of how these interventions were con-
ceptualized, developed, and implemented, and highlights60 S. S. Shin et al.
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lessons learned that could inform the replication of such
programmatic interventions in other parts of Russia and
elsewhere.
METHODS
Study Setting
Our interventions took place in the Tomsk Oblast of western
Siberia, Russia, an area of 316,900 km2, with a population
of 1,200,000. As previously described, Russia has one of the
highest rates of alcohol consumption per capita in the world.
In 2010, TB incidence in Tomsk was 73.3 per 100,000,
and TB mortality was 8.6 per 100,000.37 TB treatment ser-
vicesinTomskCityareprovidedinthreefacilities(inpatient
hospital, polyclinic, and day hospital). In 1991, the Tomsk
Oblast Tuberculosis Services implemented WHO standards
for TB care (i.e., DOTS).36 In 2000, it began a collaborative
project with our nongovernmental organization, Partners in
Health, to improve TB treatment outcomes. Patients receive
TBtherapydailyunderdirectobservation,whichisprovided
free-of-charge for a minimum of six months. Prior to the ef-
forts described below, AUD management was not integrated
into TB services. Physicians generally referred patients to
narcologists, who were solely responsible for AUD diagnosis
and management. Free on-site addiction care was available
for hospitalized patients who agreed to see the narcologist.
Treatment options included detoxiﬁcation for alcohol intox-
ication, disulﬁram, and psychotherapy; however, BCIs and
naltrexone (NTX) were not available.
Through a collaborative effort that began in 2004 and
involved Brigham and Women’s Hospital, McLean Hospital,
Partners in Health, and the Tomsk Oblast Tuberculosis
Services, we established the Tomsk Tuberculosis Alcohol
Working Group (Working Group) comprising U.S. and
Russian experts to develop and implement programmatic
and research efforts to address AUDs among TB patients
in Tomsk. Strategies were implemented in two areas:
(1) screening and specialist referral; and (2) integrated alco-
hol treatment. Screening and referral strategies using the
AlcoholUseDisorderIdentiﬁcationTest38 (AUDIT)wereim-
plementedasprogrammaticactivitieswithsupportfromthe
Global Fund to Fight AIDS, TB and Malaria, and have been
described elsewhere.39 Treatment interventions were imple-
mented under the auspices of research funded by the United
States’ National Institute of Alcohol Abuse and Alcoholism.
This study, Integrated Management of Physician-
Delivered Alcohol Care for Tuberculosis Patients(IMPACT),
wasarandomized,controlledtrialtoassesstheeffectiveness
of NTX or monthly BCIs for TB patients with AUDs as an
integral part of routine care at the Tomsk Oblast Tuberculo-
sis Services in Tomsk, Russian Federation.40 The study took
place in both inpatient and ambulatory sites of TB services
in Tomsk City. As is typical for TB treatment, patients were
initially enrolled in the hospital and then transitioned to
ambulatory care once medically stable. A total of 412 indi-
viduals were recruited, and 200 of the 306 eligible individ-
uals were enrolled. We assessed alcohol and TB treatment
outcomes at six months to determine the effect of both in-
terventions on change in alcohol consumption and favorable
TB treatment response. A total of seven physicians deliv-
ered study interventions. Of note, this was an effectiveness
trial intended to assess the impact of evidence-based alcohol
interventions when integrated into Russian TB health ser-
vices. We therefore designed study interventions with the
intent of integrating alcohol care seamlessly into routine
TB care. See Figure 1.
Data Collection
We collected qualitative data using multiple methods to al-
low for triangulation and veriﬁcation of our ﬁndings. In-
vestigators trained in ethnography carried out participant
observation during the six years of the project, including
two years of preparation with Tomsk collaborators and
four years of trial execution. For qualitative evaluation, we
deﬁned participants as TB patients with AUDs who en-
rolled in the study (study subjects), eligible patients who
were recruited but declined enrollment, and TB providers
who delivered study interventions and collected study data.
Field notes from observation of participants were analyzed
for theme and content, and ﬁndings were used to develop
semistructured interview guides for one-on-one interviews
and focus group discussion. Four one-on-one interviews and
ﬁve focus group discussions consisting of semistructured,
open-ended questions were conducted between 2008 and
2011. The objectives of these interviews were to understand
participant attitudes toward the alcohol interventions that
were implemented. Questions elicited opinions regarding
the appropriateness of the study interventions (BCI and
NTX), their effectiveness, problems or limitations in ap-
plication, and relevance for programmatic use. Individual
interviews were conducted with three of the TB physicians.
We conducted focus groups with participating providers at
two separate times; in addition, we conducted three focus
groups involving the following patients: (1) individuals who
had declined enrollment; (2) subjects randomized to BCI;
and (3) subjects randomized to NTX. Patient participants
were selected by asking the study team to identify four to
six candidates for each group. We invited candidates before-
hand and obtained oral consent for participation using a
written script for all who attended. All but one individual
agreed to participate in focus group discussions. A study
staff trained in conducting focus group discussions led theHarv Rev Psychiatry
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Initial TB diagnosis and intake, including programmatic AUDIT (n = 412) 
Agreed to undergo evaluation to assess need for alcohol care (n = 402)
Underwent CIDI evaluation for AUD (n = 392)
INTEGRATED TB & ALCOHOL CARE (randomized to BCI vs. no BCI, NTX vs. no NTX)
Withdrawn from TB treatment & study (found not to have TB) (n = 4)
Ineligible based on negative CIDI (n = 79) or other criteria (n = 7)
Eligible but declined enrollment (n = 106)
Complete TB treatment: assess TB & alcohol outcomes at six months
INTEGRATED TB & ALCOHOL CARE (randomized to BCI vs. no BCI, NTX vs. no NTX)
TB treatment (n = 196) Alcohol interventions (pharmacologic or counseling) (n = 145)
• Multidrug therapy 
administered for at least six 
months under directly 
observed therapy
• TB care for individuals with 
AUDs often inpatient for first 
three months, then transi-
tioned to outpatient setting
Pharmacologic intervention (n = 92):
• NTX provided daily along with TB 
meds under direct observation.
• Six sessions of Brief Behavioral 
Compliance Enhancement 
Treatment (5–10 minutes) 
delivered by TB provider during 
routine monthly evaluations
Counseling intervention (n = 98):
Six sessions of brief counseling 
intervention (10–20 minutes) 
delivered by TB provider during 
routine monthly evaluations
Figure 1. Flow chart of therapeutic intervention. AUD, Alcohol use disorder; AUDIT, Alcohol Use Disorder Identiﬁcation Test; BCI, brief
counseling intervention; CIDI, Composite International Diagnostic Interview; NTX, naltrexone; TB, tuberculosis.
interviews, with an observer present. Both the facilitator
and observer took notes. Sessions lasted approximately one
hour and were tape-recorded. An individual ﬂuent in Rus-
sian reviewed recordings and coded them for theme and con-
tent. We also asked subjects who had ﬁnished the assigned
treatment to complete written exit surveys six months later,
at the ﬁnal alcohol-assessment interview. Surveys asked
subjects about their experience in the trial, whether they
felt any improvement in their AUDs, and whether they per-
ceived their assigned study interventions to be effective. We
organized data into four areas: intervention design, train-
ing, intervention delivery, and outstanding challenges.
Ethical Considerations
The Partners Human Subjects Committee at Brigham and
Women’s Hospital and the Ethics Committee of State Re-
search Center of Virology and Biotechnology “Vector” in
Novosibirsk, Russia, both approved the clinical trial.
FINDINGS
Intervention Selection
Initial efforts of the Working Group focused on identify-
ing EBIs that could be readily applied as part of TB care.
We considered both behavioral and pharmacological inter-
ventions, and weighed the pros and cons of both. Tomsk
colleagues felt that behavioral interventions would poten-
tially be more acceptable to some patients who would not
want to take more medications, though some reservations
were voiced regarding the appropriateness and feasibility of
providers not trained in addictions care to deliver counsel-
ing on AUDs. Another factor was that, since prevailing Rus-
sian medical culture relies heavily on pharmacologic ther-
apy, both providers and patients might place more “faith”
in, and therefore favor, pharmacologic over behavioral in-
terventions. Based on our literature review, we considered
two interventions—BCI and NTX—to be acceptable for use
among TB patients. Literature review and expert opinion
provided reassuring experience that BCI could be effectively
delivered by nonspecialists and that no pharmacologic inter-
actions occurred between NTX and anti-TB medications. We
furthermodiﬁedourpharmacologicinterventioninresponse
to new data that medical management combined with NTX
was more effective than NTX alone.41
Intervention Adaptation
Once the Working Group identiﬁed the most appropriate
interventions, we adapted these interventions to the local
context, taking into consideration the providers, patients,62 S. S. Shin et al.
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and health system. We identiﬁed existing behavioral inter-
ventions. For BCI, we used the National Institute on Alco-
hol Abuse and Alcoholism’s 2005 manual: Helping Patients
Who Drink Too Much: A Clinician’s Guide. For medical man-
agement, we sought an intervention that would focus on
medication adherence and on goal setting to reduce alcohol
consumption, but that maintained a clear distinction from
BCI by avoiding both counseling that used problem-solving
methods and the style and techniques of motivational in-
terviewing. We identiﬁed the Brief Behavioral Compliance
Enhancement Treatment (BBCET) that was developed for
the Topiramate Clinical Protocol,42 and obtained permission
from Johnson and colleagues to adapt the manual.
While retaining the core components of each behavioral
intervention, we modiﬁed areas of content, style, and format
tobeculturallyandmedicallyappropriateforourtargetpop-
ulation. Our team developed adapted manuals and trans-
lated them into Russian. In terms of content, we adapted
the BCI to highlight the relevance of AUDs for TB patients;
we therefore provided feedback and education on the effect
of AUDs on TB risk, on the potentially increased side ef-
fects from TB therapy, and on alcohol’s detrimental effect on
treatment outcomes. The BBCET manual included guide-
lines for use of NTX in TB patients, including management
of side effects potentially caused by both NTX and TB medi-
cations, perioperative management of NTX to avoid adverse
reactions due to anesthesia and pain control, and a descrip-
tion of contraindications for NTX use, such as pregnancy
and opiate use. Stylistic modiﬁcations resulted from careful
consideration of how to deliver the BCI using motivational
interviewing in a way that would be natural in the context
of typical Russian patient-provider interactions (tradition-
ally a more authoritative relationship than in the United
States). For instance, multiple bilingual collaborators care-
fully reviewed the wording chosen for the manuals in order
to ensure that the language was neither too medical nor too
informal. This aspect of adaptation required input by Rus-
sian providers and Russian-speaking individuals trained in
motivational interviewing because the wording had to be
empathic yet respect the traditional lines of authority in
the patient-provider relationship.
As an example of cultural challenges, many TB patients
have been previously incarcerated and have been inculcated
in a prison culture with its rules and mentality, including
mistrust of authorities. Many TB doctors have worked with
TB patients for so long that they accept these social norms,
rather than try to gain the trust of the patient or provide
empathic support.
By introducing motivational-interviewingtechniques, we
confronted and, in some cases, overcame these beliefs and
behaviors on both sides of the patient-physician relation-
ship. BCI encourages both patients and providers to take
an active role in exploring changes in drinking behavior.
We found that physicians and patients were more comfort-
able when the BCI dialogues initially covered neutral top-
ics and then slowly moved into drinking-related problems
and patients’ feelings toward their drinking. Over time and
with continuous coaching, TB providers learned to be em-
pathic and provide encouragement; they were unexpectedly
rewarded by patients’ positive responses to this type of be-
havior. Our team also modiﬁed the format of both inter-
ventions to be folded into routine TB encounters. The BCI
incorporated routine aspects of the medical encounter, such
as assessment of laboratory analysis and clinical response,
as a way of providing information and feedback to the pa-
tient using motivational interviewing techniques. Likewise,
to integrate treatment delivery, health care workers admin-
istered NTX along with TB medications under directly ob-
served treatment and recorded adherence to NTX using a
form similar to that for monitoring TB treatment.
Initial Training and Ongoing Supervision
We used a train-the-trainer model for initial and ongoing
training of Tomsk TB physicians. U.S. addiction experts
trained two providers, including a Russian physician who
was based in Tomsk for the duration of the study. Training
of TB physicians took place prior to initiating the study
and included didactic teaching that reviewed both inter-
ventions, including the theoretical framework, literature
establishing efﬁcacy, and Tomsk-speciﬁc adaptations. In
addition, trainees watched a video of mock interviews (one
using motivational-interviewing style, and one not) and par-
ticipated in interactive role-play to practice motivational-
interviewing techniques. Most of the providers were not
familiar with role playing, and not all individuals were
willing to practice role playing. Provider competency was
required in order to participate in the study. We assessed
competency by performing mock sessions (BCI and BBCET)
with the Tomsk-based trainer. We also modiﬁed our train-
ing to include a one-on-one “practice session” just prior to
competency assessment, in which the Tomsk-based trainer
role-played the patient. This addition allowed for nonthreat-
ening, individualized feedback and improved the quality of
the competency-assessment interviews. All providers who
participated in competency assessment were certiﬁed.
As part of the research protocol, we established ﬁdelity
procedures that not only served to assess adherence to the
behavioral study intervention but also provided ongoing
supervision and improved provider proﬁciency during the
course of the study. The ﬁdelity-assessment team included
the Tomsk-based trainer, an addiction specialist with clini-
cal and research experience, and two Russian-speaking staff
based in the United States who were responsible for review-
ing audiotapes of study encounters and rating providersHarv Rev Psychiatry
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using a standardized ﬁdelity-assessment form that included
constructive feedback. We requested that all study encoun-
ters be audiotaped (if subjects allowed), and approximately
10% of the encounters were reviewed by the ﬁdelity team.
Weekly teleconferences enabled the U.S.-based team to re-
ceive feedback from the Tomsk trainer regarding the clini-
cal realities and challenges occurring in the ﬁeld and also
enabled the trainer to better understand the ﬁdelity re-
viewers’ reports and to relay constructive feedback to the
providers. Related to the pharmacologic intervention, we
conducted regular teleconferences in the ﬁrst year of the
study with U.S.-based specialists to review “difﬁcult cases”
of individuals receiving NTX. Discussion included manage-
ment of surgical cases, NTX-related side effects, and in-
terruption of NTX due to binges and detoxiﬁcation. We
modeled case conferences after case-discussion meetings
held with Tomsk providers when treatment of multidrug-
resistant TB was being introduced into the Tomsk TB
program. This ongoing accompaniment—that is, continual
coaching and feedback to providers during the “learning
curve” of implementation—represents a labor-intensive ne-
cessity for behavioral research but is an aspect of ongo-
ing supervision that is often overlooked during program-
matic implementation. In our experience, however, such
accompaniment is crucial in obtaining local “buy-in” and
establishing true clinical proﬁciency among participating
providers.
Intervention Delivery
At the outset we developed study protocols describing the
delivery of both interventions. Once “in the ﬁeld,” however,
many details of intervention delivery presented challenges
requiring further adaptation to the setting. Responding to
the needs of all participants (program directors, providers,
patients), we made several decisions in the course of the
project that, rather than involving amendments to the study
protocol, constituted logistical reﬁnements that allowed us
to successfully implement the study protocol. Prior to be-
ginning IMPACT, we had already implemented the written
AUDIT as part of the initial evaluation for all patients start-
ing TB treatment. This screening instrument allowed us to
identify individuals at risk for AUDs and to refer them for
moredetailedassessment.Havingsuchastreamlinedmech-
anism in place prior to study start was helpful in two ways.
AUDIT training increased TB providers’ general awareness
of AUDs, and the providers themselves quickly identiﬁed
high-risk patients and referred them to the study. Based on
our validation study, an AUDIT score of ≥8h a das e n s i t i v -
ity of 83.5% in this population, compared to a diagnosis of
alcohol abuse or dependence based on the Composite Inter-
national Diagnostic Interview (CIDI).43
During the course of the study, we eventually opted
to screen all individuals with the CIDI in order to maxi-
mize study enrollment. Consistent with our validation data,
we identiﬁed 51 patients (12.8% of the total cohort) who
scored less than 8 on the written AUDIT questionnaire
but were diagnosed with AUDs when interviewed using the
more detailed, verbally administered CIDI interview. Often,
their providers suspected AUDs in such individuals despite
AUDIT results. The programmatic implications of this ex-
perience are that AUDIT serves as a useful screening tool
but that a more careful, personalized assessment should be
pursued in cases suspected of having AUDs despite negative
AUDIT screens.
Although NTX is approved for the treatment of AUDs
in Russia, access to this medication is limited, and it is
used mainly to treat private patients for heroin addiction.44
Moreover, the Russian pharmaceutical market was unsta-
ble during our study, with frequent regulation and price
changes. We maintained a surplus supply of NTX, which
ensured continuous treatment despite disruptions in pur-
chasing mechanisms from contracted vendors. Several ad-
ministrative steps were also taken to integrate NTX into TB
care: obtaining authorization from the TB program to use
NTX; and training ancillary staff to administer NTX along
with TB medications under direct observation, to monitor
for side effects, and to record administration.
Despite initial concerns that patients would reject NTX
due to the increased pill burden, this occurred with only
three participants. In fact, all providers and patients who
participated in focus group discussions and 75% of patients
who completed the exit survey perceived the medication
to be effective. Overall, the mean adherence to NTX was
81.5% (standard deviation = 37.4%), deﬁned as the per-
centage of doses ingested in relation to the total number
of doses prescribed prior to study completion or withdrawal.
For reference, the mean adherence to DOTS for TB therapy
was 86.7% (standard deviation = 8.5%). Such high rates of
NTXadherencelikelyreﬂectthedeliverysystemdesignedto
streamline administration and present minimal additional
burden to staff and patients. NTX adherence was higher
in the ﬁrst three months of therapy than in the last three
months (85% vs. 74%). This trend could be due to greater lo-
gistical challenges in administering directly observed NTX
when patients transitioned to outpatient care, as they in-
creasedtheirbingedrinking(zapoi)andtendedtomissdaily
appointments.
In terms of delivering the behavioral interventions, we
envisioned both the BCI and BBCET to be incorporated into
routine monthly TB evaluations delivered by TB physicians.
Although both interventions were brief (15–20 minutes for
BCI; 5–10 minutes for BBCET), their delivery did involve an
additional time burden during routine clinical encounters.
Importantly,theTBhospitaldirectoractivelysupportedthis64 S. S. Shin et al.
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collaboration and allowed providers to have protected time
to carry out study protocols. We did not provide patient in-
centives for counseling sessions (only for data-collection in-
terviews) in order to avoid introducing an artiﬁcial incentive
for attending BCI and BBCET sessions.
Manuals for both BCI and BBCET provided struc-
ture that helped providers deliver the interventions
correctly—particularly in terms of content and format. Ad-
herence to BCI style (motivational interviewing), however,
was more challenging. Becoming proﬁcient and comfortable
in motivational interviewing required practice and ongo-
ing feedback, as previously described. Serial focus group
interviews with providers revealed that initial skepticism
toward the behavioral interventions eventually gave way to
endorsement and perceived effectiveness. Overall, among
the scheduled BCI and BBCET encounters, 51% of BCI and
57% of BBCET encounters were successfully delivered. Sim-
ilar to trends observed with NTX, a greater proportion of
sessions was completed during the ﬁrst three months (66%
for BCI; 65% for BBCET) than in the last three months of
TB therapy (36% for BCI; 49% for BBCET).
During the course of the study, several unexpected
lessons enriched our learning experience. One unexpected
beneﬁt of NTX was its use as a “bridge to surgery.” Surgery
is a mainstay adjunctive treatment for TB, particularly for
individuals with focal, resectable disease. Many individuals
with indications for surgery in Russia are unable to un-
dergo surgery due to the excessive risk associated with on-
going heavy drinking, including the inability to follow-up
with pre- and postoperative assessments and the morbidity
associated with severe postsurgical withdrawal. TB physi-
cians worked closely with patients and surgeons to decrease
alcohol intake prior to surgery and follow protocols on pe-
rioperative NTX management. Several patients who might
otherwise not have been able to tolerate surgery underwent
successful procedures, and preparation for surgery provided
additional motivation to cut down on drinking.
Another aspect of care that heavily inﬂuenced the de-
livery of alcohol treatment was the treatment site. Alcohol
interventions were more easily integrated into inpatient TB
care than into outpatient services. Hospital physicians and
patients had more time to coordinate care and deliver un-
hurried behavioral interventions. Patients lived in a “com-
munity” while in the hospital, in which common opinion
(e.g., favorable attitudes toward the study) enhanced their
willingness to participate in study activities. By contrast,
challenges to implementation in the ambulatory setting in-
cluded lower adherence to TB care (including medications
and appointments) and less interest on the part of both
providers and patients, despite efforts to carry out simi-
lar programmatic accompaniment in that setting. Based on
discussions with providers, an ideal programmatic strategy
for integrating alcohol and TB care would be to target in-
patients, particularly those who are likely to stay longer in
the hospital due to unstable social situations or multidrug-
resistant TB. Furthermore, the goal of the intervention may
depend on the setting. For instance, even short-term reduc-
tion in alcohol use during the intensive phase of TB treat-
ment could improve the chances of TB cure, whereas achiev-
ing long-term remission from alcohol use could require the
incorporation of additional strategies, such as training in
relapse-prevention skills and facilitating family or commu-
nity supports for a sober lifestyle.
Ongoing Challenges
Transitioning from an effectiveness trial to a sustainable
programmatic intervention would present additional chal-
lenges. If proven effective, sustained integration of alco-
hol care into TB services would require secure funding for
NTX, training, and oversight, as well as an institutional
commitment to maintain such interventions as the ongoing
standard of care. Moreover, the external validity of any clin-
ical trial—even an effectiveness trial—is limited by inher-
entdifferencesinparticipantcharacteristics,includingtheir
motivation to participate, the inﬂuence of study compensa-
tion, and any indirect support received due to participation
in the study. Finally, Tomsk Oblast Tuberculosis Services
has served as a model of innovative programs for the past
two decades, including early adoption of DOTS and the im-
plementation of a model program for multidrug-resistant
TB. Adapting the study interventions to other TB programs
inRussia andelsewhere requiresapackageof “deliverables”
designed for dissemination, such as materials for training
and patient care, mechanisms for monitoring and evalua-
tion, and ﬁnancial resources.
DISCUSSION
The IMPACT study involved the implementation of two
evidence-based alcohol interventions in a novel context: in-
tegrated into TB services in a resource-limited setting. The
process of intervention development, training, and deliv-
ery highlights key considerations for global efforts to ap-
ply evidence-based interventions to new populations and
health infrastructures, particularly when adapting an EBI
that has been well studied in upper-income countries but
not in resource-limited settings.
The primary objective of adapting an EBI to a different
cultural context is to produce the cultural equivalent of a
model intervention program. Research is mixed but has
demonstrated the beneﬁt of adapting EBIs, rather than
using the original EBI45 or creating new programs de
novo.46 The EBI can be modiﬁed in form (characteristics
of delivery person, channel, or location of delivery)47 orHarv Rev Psychiatry
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in content.48 Content can itself be modiﬁed superﬁcially
or on a deeper, structural level.49 Several models for EBI
adaptation have been developed, such as the Diffusion
of Effective Behavioral Interventions (DEBI) project by
the Centers for Disease Prevention and Control50 and
the ADAPT-ITT model by the Emory Center for AIDS
Research. Both models include needs assessment, selection
of preferred EBI, identiﬁcation of qualiﬁed experts, pilot re-
search, and efﬁcacy evaluation.51,52 Although our study did
not explicitly follow either the DEBI or ADAPT-ITT model,
we included their common core principles in our process.
Adaptation of EBIs in resource-poor settings presents
distinct challenges. Models for adapting EBIs have been
generally geared toward cultural minority groups in the
United States, but little of the literature addresses the
unique challenges of adapting EBIs where resources are
scarce.47,53,54 If an intervention is perceived, for example,
as irrelevant or culturally inappropriate, failure of local
communities to endorse the intervention may result in
its failure to prove effective.45 This phenomenon may be
complicated further in communities that have, in the past,
experienced what proved to be failed attempts to implement
poorly adapted interventions. Perhaps most importantly,
the inﬂuence of structural factors—for example, the lack
of health services; barriers to accessing health care such as
cost and distance; and socioeconomic inequalities leading to
greater health risk and less health-seeking behavior among
women, the poor, and stigmatized populations—on individ-
ual behavior is greatest in resource-limited settings.55,56
Therefore, strategies to implement evidence-based care in
such settings must include not only the intervention but
programmatic buttressing to allow vulnerable populations
to access and adhere to these services.
In summary, a wealth of literature establishes the
efﬁcacy of numerous alcohol interventions. Nonetheless,
getting these interventions to work in the “real world”
can be challenging—and even more so in the context of
implementation in resource-limited settings where socioe-
conomic inequalities, limited access to health services,
and inadequate health infrastructure make treatment of
chronic mental health problems difﬁcult. One of the great-
est challenges in such settings is delivering longitudinal
alcohol care to marginalized individuals who are unlikely to
seek help and to remain in treatment for alcohol problems.
Nonetheless, our experience implementing alcohol care
for TB patients in Tomsk highlights some of the key
aspects to effectively disseminating evidence-based care:
(1) knowledge of local needs and resources, (2) collab-
orative effort with iterative local input, (3) delivery of
alcohol services as an integral component of treatment
for other chronic medical conditions, (4) task shifting to
nonspecialized providers who deliver “front-line primary
care services” to the community, (5) programmatic “accom-
paniment” throughout the process of implementation to
ensure seamless integration and clinical proﬁciency, and
(6) commitment of programmatic leadership to dedicate
ﬁnancial and human resources to sustained operations.
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